SPI Infoamtion

1. Overview
1.1 Heart Failure (HF)
1.1.1 Heart Failure as a disease and its implications
1.1.2 Heart Failure stages and mortality rates within those respective stages
1.2 Current Treatment Options for Heart Failure
1.2.1 Various treatment options for heart failure
1.2.2 Treatment options for different stages of heart failure
1.2.3 Use of LVADs for BTT and DT indications

2. Market Size
2.1 Increasing heart failure cases - heart failure a leading cause of death globally
2.2 Global LVAD market growth - BTT and DT markets
2.3 US and OUS BTT and DT market growth
2.4 Heart failure cases in Asian region
2.5 BTT and DT market penetration
2.6 US LVAD market growth projection on the basis of target population

3. Cost and Reimbursement in LVAD Market
3.1 Developments in medical therapy costs over past years
3.2 LVAD Reimbursement developments over the past years

4. LVAD Market Dynamics
4.1 Growth Drivers
4.1.1 Under-Penetrated Market
4.1.2 Growing Patient List and Limited Donor Hearts Available
4.1.3 Expected Growth in DT Application
4.1.4 Increasing Referrals
4.1.5 Bridge-to-decision (BTD) guidelines
4.1.6 Expansion in the number of LVAD centers
4.2 Barriers for DT adoption
4.2.1 Geographic Limitations
4.2.2 Physician Education

5. Competition in LVAD Market
5.1 Key competitive factors for the industry players
5.2 Sales and market share growth of key players
5.3 Clinical trials by different players
5.4 VADs currently in development stages and BTT product launches

6. Company Profiles
6.1 Thoratec Corporation
6.1.1 Business Overview
6.1.2 Business Strategies
6.1.3 Partnership with Leading Heart Centers
6.1.4 Greater use of VADs in existing segments
6.1.5 Increase presence in Cardiovascular and ITC segments
6.2 HeartWare International, Inc.
6.2.1 Business Overview
6.2.2 Business Strategies
6.2.3 Commercially launch the HeartWare System in Europe and Australia
6.2.4 Obtain regulatory approval in the United States
6.2.5 Continue sales and marketing activities
6.2.6 Focus on continuous product development
6.3 WorldHeart Corporation (USA)
6.3.1 Business Overview
6.3.2 Business Strategies
6.3.3 Consolidation Plan
6.3.4 Marketing, Manufacturing and Distribution Strategy
6.4 Abiomed, Inc.
6.4.1 Business Overview
6.4.2 Business Strategies
6.4.3 Global distribution and clinical expertise in the cath lab
6.4.4 Establish recovery awareness through clinical data and published scientific studies
6.4.5 Enhance the product portfolio

List of Tables
NYHA Classification of Heart Failure
Global LVAD Application (BTT & DT) Market Growth (2007A-2013E)
US and Outside US BTT Market Growth (2007A-2013E)
US and Outside US DT Market Opportunity (2007A-2013E)
US LVAD Market Opportunity (2007A-2012E)
CPT Codes for VAD Implantation
US Sales & Market Share of Major Players (2007-2010E)
US VAD Market Share Growth (2007A-2010E) (Part 1)
US VAD Market Share Growth (2011E-2015E) (Part 2)
Outside US Sales & Market Share of Major Players (2007-2013E)
Worldwide Sales & Market Share of Major Players (2007-2013E)
BTT Product Launches

List of Charts
Mortality Rates of Various HF Classes
Stages of HF and associated interventions
Breakdown of HF Market (2008)
Diagnosed Congestive Heart Failure Population (2007A-2015E)
Global LVAD Market Growth Estimates (2008A-2013E)
BTT Market Penetration Estimates (2007A-2013E)
DT Market Penetration Estimates (2007A-2013E)
Medical Therapy Costs over last 2 years for End-Stage HF Patients
LVAD Reimbursement Trend (2002-2009)
Sales Growth of Thoratec Corporation (2004-2008)
Sales Growth of HeartWare International, Inc. (2006-2008)
Sales Growth of WorldHeart Corporation (USA) (2004-2008)
Sales Growth of Abiomed, Inc. (2005-2009)